Ranolazine
- Generic Name
- Ranolazine
- Brand Names
- Aspruzyo Sprinkle, Ranexa, Ranexa (previously Latixa)
- Drug Type
- Small Molecule
- Chemical Formula
- C24H33N3O4
- CAS Number
- 95635-55-5
- Unique Ingredient Identifier
- A6IEZ5M406
- Background
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
- Indication
Ranolazine is indicated for the treatment of chronic angina. It can be used alone or in conjunction with nitrates, beta-blockers, angiotensin receptor blockers, anti-platelet drugs, calcium channel blockers, lipid-lowering drugs, and ACE inhibitors.
Ranolazine has also been used off-label for the treatment of certain arrhythmias, including ventricular tachycardia, however, this use is not strongly supported by scientific evidence. Ranolazine has also been studied for the treatment of acute coronary syndrome, microvascular coronary dysfunction, arrhythmia, and glycemic control, which are not yet approved indications.
- Associated Conditions
- Chronic Angina, Ventricular Arrhythmia
Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT01546558
- Locations
- 🇺🇸
SeaView Research Inc., Miami, Florida, United States
Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT01546597
- Locations
- 🇺🇸
Cetero Research, San Antonio, Texas, United States
Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2014-08-19
- Lead Sponsor
- Menarini Group
- Target Recruit Count
- 241
- Registration Number
- NCT01534962
- Locations
- 🇩🇪
Universitätsmedizin Göttingen (UMG), Kardiologie und Pneumologie, Goettingen, Lower Saxony, Germany
🇮🇹FONDAZIONE IRCCS, Dip. Cardiotoracovascolare (U.C.C.), Pavia, Lombardy, Italy
🇪🇸Hospital Clínic i Provincial de Barcelona, Servicio de Cardiología-Sección de Arritmias, Barcelona, Catalonia, Spain
Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 134
- Registration Number
- NCT01522651
- Locations
- 🇬🇧
Investigational Site, London, England, United Kingdom
The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 10
- Registration Number
- NCT01505179
- Locations
- 🇺🇸
University of California, San Diego, San Diego, California, United States
Ranolazine for Improving Symptoms of Palpitations
- First Posted Date
- 2011-12-20
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 100
- Registration Number
- NCT01495520
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 431
- Registration Number
- NCT01494987
- Locations
- 🇺🇸
Clinical Research Advantage/Desert Clinical Research, LLC, Mesa, Arizona, United States
🇺🇸Desert Sun Clinical Research, LLC, Tucson, Arizona, United States
🇺🇸Southland Clinical Research Center, Inc., Fountain Valley, California, United States
Ranolazine Loading to Prevent PCI-induced Myocardial Injury
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 100
- Registration Number
- NCT01491061
- Locations
- 🇮🇹
San Raffaele Pisana, Rome, Italy
Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 100
- Registration Number
- NCT01490255
- Locations
- 🇮🇹
San Raffaele Pisana, Rome, Italy
🇮🇹University La Sapienza, Rome, Italy
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 465
- Registration Number
- NCT01472185
- Locations
- 🇺🇸
Thunderbird Internal Medicine/Clinical Research Advantage, Glendale, Arizona, United States
🇺🇸North Central Arkansas Medical Associates, Mountain Home, Arkansas, United States
🇺🇸Desert Sun Clinical Research, LLC, Tucson, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.